{"schema_version":"secwatch.filing_event.v1","accession":"0001069530-22-000061","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.505017+00:00","generated_at":"2026-06-21T13:48:32.715111+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cassava Sciences closes $50M registered direct offering of 1.67M shares at $30/share","bullets":["Gross proceeds ~$50M from 1,666,667 shares at $30; net proceeds ~$47.3M after fees.","H.C. Wainwright acted as exclusive placement agent; JonesTrading and Perella Weinberg as advisors.","Proceeds to fund working capital and development of simufilam, its lead Alzheimer's candidate.","Offering closed Nov. 22, 2022; shares sold under existing shelf registration statement.","90-day lock-up on company share sales; prohibition on variable-rate transactions for 90 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001069530-22-000061","json":"https://secwatch.observer/filing/0001069530-22-000061.json","markdown":"https://secwatch.observer/filing/0001069530-22-000061.md","text":"https://secwatch.observer/filing/0001069530-22-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/0001069530-22-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/sava-20221118x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:48:32.715111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b533f603ecbd3cd9208b38b44e90c3f6167de35e","claim":"FILANA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain investors valued at approximately $50 million (effective 2022-11-18).","evidence_excerpt":"On November 18, 2022, Cassava Sciences, Inc. (the “ Company ” ) entered into a Securities Purchase Agreement (the “ Agreement ” ) with certain investors (each, including its successors and assigns, a “ Purchaser, ” and collectively the “ Purchasers ” ), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “ Offering ”) 1,666,667 shares (the “ Shares ” ) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ” ), at an offering price of $30.00 per share, for gross proceeds of approximately $50 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/0001069530-22-000061-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $50 million"},{"label":"Effective","value":"2022-11-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}